EA
REGN icon

Emerald Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Emerald Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-357
Closed -$375K – 267
2024
Q3 		$375K Hold
357
– – 0.01% 191
2024
Q2 		$375K Sell
357
-202
-36% -$196K 0.02% 185
2024
Q1 		$538K Sell
559
-53
-9% -$50.4K 0.02% 175
2023
Q4 		$538K Sell
612
-65
-10% -$53.5K 0.02% 173
2023
Q3 		$557K Buy
677
+272
+67% +$214K 0.03% 165
2023
Q2 		$291K Buy
+405
New +$312K 0.01% 193
2020
Q4 		– Sell
-557
Closed -$312K – 337
2020
Q3 		$312K Buy
+557
New +$338K 0.01% 206
2013
Q3 		– Sell
-4,368
Closed -$982K – 355
2013
Q2 		$982K Buy
+4,368
New +$1.02M 0.06% 237

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return